ATE523786T1 - In-vitro-verfahren zur prognose des fortschreitens einer krebserkrankung und des ausgangs für einen patienten sowie verfahren zur durchführung des verfahrens - Google Patents

In-vitro-verfahren zur prognose des fortschreitens einer krebserkrankung und des ausgangs für einen patienten sowie verfahren zur durchführung des verfahrens

Info

Publication number
ATE523786T1
ATE523786T1 AT06809203T AT06809203T ATE523786T1 AT E523786 T1 ATE523786 T1 AT E523786T1 AT 06809203 T AT06809203 T AT 06809203T AT 06809203 T AT06809203 T AT 06809203T AT E523786 T1 ATE523786 T1 AT E523786T1
Authority
AT
Austria
Prior art keywords
patient
outcome
predicting cancer
cancer progress
vitro method
Prior art date
Application number
AT06809203T
Other languages
English (en)
Inventor
Jerome Galon
Franck Pages
Wolf-Herman Fridman
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE523786(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE523786T1 publication Critical patent/ATE523786T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06809203T 2005-10-19 2006-09-28 In-vitro-verfahren zur prognose des fortschreitens einer krebserkrankung und des ausgangs für einen patienten sowie verfahren zur durchführung des verfahrens ATE523786T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05292200A EP1777523A1 (de) 2005-10-19 2005-10-19 In-vitro-Verfahren zur Prognose einer Tumorprogression und des Ergebnisses bei einem Patienten sowie Mittel zur Durchführung dieses Verfahrens
US76435606P 2006-02-02 2006-02-02
PCT/IB2006/003168 WO2007045996A1 (en) 2005-10-19 2006-09-28 An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method

Publications (1)

Publication Number Publication Date
ATE523786T1 true ATE523786T1 (de) 2011-09-15

Family

ID=36129834

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06809203T ATE523786T1 (de) 2005-10-19 2006-09-28 In-vitro-verfahren zur prognose des fortschreitens einer krebserkrankung und des ausgangs für einen patienten sowie verfahren zur durchführung des verfahrens

Country Status (8)

Country Link
US (5) US8481271B2 (de)
EP (14) EP1777523A1 (de)
JP (3) JP5256038B2 (de)
AT (1) ATE523786T1 (de)
DK (2) DK2733493T3 (de)
ES (12) ES2480690T3 (de)
PL (1) PL2733493T3 (de)
WO (1) WO2007045996A1 (de)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120064089A1 (en) * 2002-11-15 2012-03-15 Morehouse School Of Medicine Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration
US20120135415A1 (en) * 2002-11-15 2012-05-31 Morehouse School Of Medicine Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP2032719A2 (de) * 2006-06-02 2009-03-11 GlaxoSmithKline Biologicals S.A. Verfahren zur identifizierung des ansprechens bzw. nichtansprechens eines patienten auf eine immuntherapie
US9464324B2 (en) * 2006-07-14 2016-10-11 The United States of America as represented by the Secretary, DHHS Methods of determining the prognosis of an adenocarcinoma
CA2671538A1 (en) 2006-12-14 2008-06-26 Leonard G. Presta Engineered anti-tslp antibody
AU2008300338A1 (en) * 2007-06-04 2009-03-26 Diagnoplex Biomarker combinations for colorectal cancer
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
GB0723179D0 (en) * 2007-11-27 2008-01-02 Immunovia Ab Diagnostic methods and arrays for use in the same
WO2009120800A2 (en) * 2008-03-25 2009-10-01 University Of Southern California Prognostic panel for urinary bladder cancer
US8921074B2 (en) * 2008-04-10 2014-12-30 Genenews, Inc. Method and apparatus for determining a probability of colorectal cancer in a subject
BRPI0913108A2 (pt) * 2008-05-29 2017-06-20 Trangene S A método ex-vivo para testar se um paciente responderá terapeuticamente a um método de tratamento, uso de níveis de células exterminadores naturais ativadas como um biomarcador, e, kit
JP5568807B2 (ja) * 2008-06-06 2014-08-13 静岡県 プロテオミクス解析を用いたメラノーママーカーの同定
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
CA2758041A1 (en) * 2009-04-16 2010-10-21 National Research Council Of Canada Process for tumour characteristic and marker set identification, tumour classification and marker sets for cancer
KR101572463B1 (ko) * 2009-08-25 2015-11-27 베르그 엘엘씨 에피메타볼릭 쉬프터(조효소 ｑ10)를 사용하는 육종의 치료 방법
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
PH12012500843A1 (en) 2009-11-04 2019-07-10 Merck Sharp & Dohme Engineered anti-tslp antibody
WO2011075744A1 (en) 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120156701A1 (en) * 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3178944B1 (de) 2010-01-11 2019-05-15 Genomic Health, Inc. Verfahren zur verwendung von genexpression zur bestimmung der wahrscheinlichkeit des klinischen verlaufs von nierenkrebs
AU2015202116B2 (en) * 2010-01-11 2017-06-08 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CA2787783A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
CA2787755A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
WO2011094483A2 (en) * 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune gene signatures in cancer
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
SG187045A1 (en) 2010-08-13 2013-02-28 Somalogic Inc Pancreatic cancer biomarkers and uses thereof
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images
CA2811015A1 (en) 2010-09-15 2012-03-22 Almac Diagnostics Limited Molecular diagnostic test for cancer
JP5784294B2 (ja) 2010-09-22 2015-09-24 シスメックス株式会社 細胞分析装置および細胞分析方法
PT2619576T (pt) * 2010-09-24 2020-09-14 Niels Grabe Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro
WO2012045888A1 (en) * 2010-10-08 2012-04-12 Epiontis Gmbh Method for determining cancer patient survival based on analyzing tumor-infiltrating overall t-lymphocytes
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US9593377B2 (en) 2010-12-02 2017-03-14 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with cancer and methods of use thereof
CN103608680A (zh) * 2010-12-14 2014-02-26 詹姆士·W·里拉尔德 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途
DK3141617T3 (en) * 2011-01-11 2019-02-25 Inst Nat Sante Rech Med PROCEDURE FOR PREVENTING THE CANCER OF A CANCER ON A PATIENT BY ANALYZING GENEPRESSION
ES2800316T3 (es) * 2011-06-13 2020-12-29 Tla Targeted Immunotherapies Ab Tratamiento del cáncer
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
WO2013067198A1 (en) * 2011-11-01 2013-05-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene signature for the prediction of nf-kappab activity
JP2014533100A (ja) * 2011-11-04 2014-12-11 オスロ ウニヴェルスィテーツスィーケフース ハーエフＯｓｌｏ Ｕｎｉｖｅｒｓｉｔｅｔｓｓｙｋｅｈｕｓ Ｈｆ 結腸直腸癌の分析のための方法およびバイオマーカー
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
WO2013107907A1 (en) * 2012-01-20 2013-07-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for the prognosis of survival time of a patient suffering from a solid cancer
JP5970560B2 (ja) * 2012-01-20 2016-08-17 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｂ細胞の密度に基づいて、固形癌に苦しむ患者の生存時間を予測するための方法
US20130203614A1 (en) 2012-02-08 2013-08-08 Jerome Galon Methods for predicting the survival time of a patient suffering from a solid cancer
SG11201408107RA (en) * 2012-06-14 2015-01-29 Inserm Inst Nat De La Santé Et De La Rech Médicale Method for quantifying immune cells in tumoral tissues and its applications
WO2014009535A2 (en) 2012-07-12 2014-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
CN102854322A (zh) * 2012-07-31 2013-01-02 吴克 一种vefg受体酶联诊断试剂盒及其制备方法
LT2880180T (lt) 2012-08-06 2019-01-25 Institut National De La Santé Et De La Recherche Médicale (Inserm) Būdai ir rinkiniai, skirti vėžiu sergančių pacientų atrankai
DK3435084T3 (da) 2012-08-16 2023-05-30 Mayo Found Medical Education & Res Prostatakræftprognose under anvendelse af biomarkører
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
CA2890161A1 (en) * 2012-11-05 2014-05-08 Novigenix Sa Biomarker combinations for colorectal tumors
US10260103B2 (en) 2012-11-27 2019-04-16 Pontificia Universidad Catolica De Chile Compositions and methods for diagnosing thyroid tumors
WO2014093623A1 (en) * 2012-12-12 2014-06-19 University Of Washington Through Its Center For Commercialization Method and assays for cancer prognosis using jak2
ES2914814T3 (es) 2012-12-17 2022-06-16 Pf Argentum Ip Holdings Llc Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc
EP3361255B1 (de) 2013-01-17 2020-03-11 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
US20160040247A1 (en) * 2013-03-15 2016-02-11 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the diagnosis, prognosis, and tratment of cancer metastasis
KR102389677B1 (ko) 2013-03-15 2022-04-21 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
JP2016521979A (ja) 2013-05-30 2016-07-28 ジェノミック ヘルス， インコーポレイテッド 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
EP3022561B1 (de) * 2013-07-15 2019-08-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur vorhersage der überlebenszeit eines patienten, der an solidem krebs leidet
CN111879948A (zh) * 2013-10-17 2020-11-03 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
CA2935903A1 (en) 2014-01-09 2015-07-16 Hadasit Medical Research Services And Development Ltd. Improved cell compositions and methods for cancer therapy
JP6605506B2 (ja) 2014-02-24 2019-11-13 ヴェンタナ メディカル システムズ， インク． ＣＤ３、ＣＤ８、ＣＤ２０及びＦｏｘＰ３の同時検出によりがんに対する免疫応答をスコア化するための方法、キット、及びシステム
EP3119908A4 (de) * 2014-03-11 2018-02-21 The Council Of The Queensland Institute Of Medical Research Bestimmung der aggressivität von krebs, prognose und ansprechempfindlichkeit auf eine behandlung
WO2015157623A1 (en) * 2014-04-11 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune gene signatures in urothelial carcinoma (uc)
ES2916923T3 (es) 2014-07-11 2022-07-06 Ventana Med Syst Inc Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
WO2016073760A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
EP3073268A1 (de) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker-tafel zur diagnose von krebs
WO2016181912A1 (ja) * 2015-05-08 2016-11-17 学校法人 川崎学園 免疫因子を指標とした肺腺癌の予後演算式作成方法と予後推定方法
JP6932365B2 (ja) * 2015-05-14 2021-09-08 公立大学法人大阪 スキルス性胃癌の治療剤、及び胃癌の予後の予測方法
WO2016191504A1 (en) 2015-05-26 2016-12-01 Incelldx, Inc. Methods of assessing cellular breast samples and compositions for use in practicing the same
WO2017024019A1 (en) * 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
JP6363652B2 (ja) * 2015-08-10 2018-07-25 中國醫藥大學附設醫院Ｃｈｉｎａ Ｍｅｄｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｈｏｓｐｉｔａｌ 樹状細胞腫瘍ワクチンの適性評価方法及び生存率の予測方法
EP3365372A1 (de) * 2015-10-22 2018-08-29 Jounce Therapeutics, Inc. Gensignaturen zur bestimmung der icos-expression
RU2605310C1 (ru) * 2015-12-01 2016-12-20 Федеральное государственное бюджетное учреждение науки Институт физиологии природных адаптаций Уральского отделения Российской академии наук Способ диагностики риска формирования дефицита противоопухолевой иммунной защиты
EP3699294A1 (de) * 2015-12-04 2020-08-26 Agency for Science, Technology and Research Klinische korrelate der immuntherapieeffizienz
WO2017141988A1 (ja) * 2016-02-19 2017-08-24 コニカミノルタ株式会社 がんまたは免疫系が関係する疾患の診断または治療のための情報取得方法
CN105911292B (zh) * 2016-05-19 2018-06-26 深圳市衍生生物科技有限公司 用于组合分析CD11c+CD11b+ DC亚群以及其分化程度和功能的试剂盒及方法
EP3465201A4 (de) 2016-06-06 2020-08-26 Astute Medical, Inc. Verwaltung von akuter nierenverletzung mit insulinähnlichem wachstumsfaktorbindendem protein 7 und gewebehemmer der metalloproteinase 2
US9990713B2 (en) * 2016-06-09 2018-06-05 Definiens Ag Detecting and visualizing correlations between measured correlation values and correlation reference values of a pathway
US12158399B2 (en) 2016-08-05 2024-12-03 Duke University CaMKK2 inhibitor compositions and methods of using the same
EP3504348B1 (de) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Verwendung von genomischen signaturen zur vorhersage des ansprechens von patienten mit prostatakrebs auf postoperative strahlentherapie
JP2019534303A (ja) * 2016-11-11 2019-11-28 メディミューン，エルエルシー 非小細胞肺がんを治療するための抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体
JP7235508B2 (ja) * 2016-11-24 2023-03-08 第一三共株式会社 Ｐｄ－１免疫チェックポイント阻害剤による治療に対するがんの感受性を予測する方法
WO2018146155A1 (en) 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Tim-3 for assessing the severity of cancer
EP3593140A4 (de) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. Subtypisierung von prostatakrebs zur vorhersage der reaktion auf eine hormontherapie
SMT202300418T1 (it) 2017-05-30 2024-01-10 Bristol Myers Squibb Co Trattamento di tumori positivi per lag-3
EP3630179A2 (de) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Zusammensetzungen mit einem anti-lag-3-antikörper oder einem anti-lag-3-antikörper und einem anti-pd-1-oder anti-pd-l1-antikörper
CN111201438A (zh) 2017-06-02 2020-05-26 朱诺治疗学股份有限公司 与和细胞疗法相关的毒性有关的制品和方法
JP7024957B2 (ja) * 2017-07-04 2022-02-24 株式会社Ｄｎａチップ研究所 大腸癌の異時性転移の有無を予測する方法およびそれに用いるキット
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
EP3659110A1 (de) * 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Verfahren und systeme zur auswertung eines immunzelleninfiltrats in tumorproben
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
CN111295394B (zh) 2017-08-11 2024-06-11 豪夫迈·罗氏有限公司 抗cd8抗体及其用途
WO2019089858A2 (en) * 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019108135A1 (en) * 2017-11-30 2019-06-06 Singapore Health Services Pte. Ltd. A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient
GB201801067D0 (en) 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
DK3746790T3 (da) 2018-01-31 2023-12-11 Ventana Med Syst Inc Fremgangsmåder og systemer til evaluering af immuncelleinfiltrat i kolorektal stadie III cancer
IL276117B1 (en) 2018-02-12 2026-04-01 Hadasit Med Res Service Modulating the expression of SLAMF6 variants for cancer treatment
WO2019164870A1 (en) * 2018-02-20 2019-08-29 Medimmune, Llc Expression of signature mrnas for identifying patients responsive to anti-pd-l1 antibody therapy
US20210018507A1 (en) * 2018-03-04 2021-01-21 Mazumdar Shaw Medical Foundation Sall.ivary protein biomarkers for the diagnosis and prognosis of head and neck cancers, and precancers
AU2019236328B2 (en) 2018-03-16 2025-10-09 Zoetis Services Llc Peptide vaccines against Interleukin-31
TWI784324B (zh) * 2018-04-12 2022-11-21 美商凱特製藥公司 利用腫瘤微環境之特性之嵌合受體t細胞治療
WO2019234221A1 (en) * 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
CN108949982B (zh) * 2018-07-09 2021-10-26 中国医科大学附属第一医院 一种利用免疫共刺激分子评价胶质瘤临床预后的方法
US12174192B2 (en) 2018-07-12 2024-12-24 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
EP3820522A4 (de) * 2018-07-12 2022-05-18 Corvus Pharmaceuticals, Inc. Verfahren zum nachweis und zur therapie von krebs mit aktivierung des adenosinsignalwegs
US20210381058A1 (en) * 2018-10-01 2021-12-09 Nantomics, Llc Evidence based selection of patients for clinical trials using histopathology
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102198404B1 (ko) * 2019-04-15 2021-01-05 고려대학교 산학협력단 대장암에서 항암제 내성과 관련된 cd133 및 이의 용도
WO2020256868A1 (en) * 2019-05-16 2020-12-24 Trustees Of Boston University Immune system modulators for the treatment of squamous lung premalignancy
WO2020235943A1 (ko) * 2019-05-21 2020-11-26 (주)아큐레시스바이오 암의 진단용 조성물
CN114072676B (zh) 2019-06-03 2024-07-12 法国国家卫生及研究医学协会 调节治疗方案的方法
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
CN110488015A (zh) * 2019-08-27 2019-11-22 成都和同易创生物科技有限公司 趋化因子cxcl14在预测结肠癌预后中的应用
US20230047712A1 (en) * 2019-10-29 2023-02-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treatments Based Upon Molecular Response to Treatment
CA3151629A1 (en) 2019-11-07 2021-05-14 Laura E. BENJAMIN Classification of tumor microenvironments
CN110895280B (zh) * 2019-12-03 2022-11-18 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于预测鼻咽癌转移的免疫评分及其应用
WO2021119761A1 (en) 2019-12-20 2021-06-24 Hudson Institute of Medical Research Cxcl10 binding proteins and uses thereof
CN115243714A (zh) * 2020-03-06 2022-10-25 匹兹堡大学联邦系统高等教育 用于治疗癌症的表达irf调节剂的溶瘤病毒
CN111458509B (zh) * 2020-04-14 2023-09-22 中国人民解放军海军军医大学第三附属医院 肝细胞癌预后评估的生物标志物及其试剂盒和方法
JP7741831B2 (ja) 2020-06-30 2025-09-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
CN115997123A (zh) 2020-06-30 2023-04-21 国家医疗保健研究所 用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
FR3112210A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
CN111638342A (zh) * 2020-07-08 2020-09-08 上海市浦东新区公利医院(第二军医大学附属公利医院) Sox17蛋白在制备肾透明细胞癌诊断或预后评估试剂盒中的应用
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
CN112365951B (zh) * 2020-11-24 2024-03-08 竹安（北京）生物科技发展有限公司 一种基于免疫检测的肿瘤用药指导系统及方法
CN112489800B (zh) * 2020-12-03 2024-05-28 安徽医科大学第一附属医院 一种前列腺癌患者的预后评估系统及其应用
KR102427057B1 (ko) * 2020-12-04 2022-07-29 전남대학교산학협력단 단일섬유종양/혈관주위세포종 전이 진단 또는 예후 분석용 바이오 마커 및 이를 이용한 진단방법
JP7719455B2 (ja) * 2020-12-21 2025-08-06 公立大学法人和歌山県立医科大学 がん罹患者の全生存期間を予測する方法
EP4026918A1 (de) 2021-01-12 2022-07-13 Koninklijke Philips N.V. Vorhersage eines ergebnisses eines patienten mit kolorektalkrebs
US20220267445A1 (en) * 2021-02-17 2022-08-25 Novocure Gmbh Methods and Compositions for Determining Susceptibility to Treatment with Checkpoint Inhibitors
CN113025716A (zh) * 2021-03-02 2021-06-25 北京大学第一医院 一种用于人肿瘤分级的基因组合及其用途
EP4321625A4 (de) * 2021-04-06 2025-03-05 Industry Foundation of Chonnam National University Verfahren zur vorhersage der prognose und des ansprechens auf eine krebstherapie bei krebspatienten
KR102865613B1 (ko) * 2021-04-06 2025-09-30 전남대학교산학협력단 암환자의 예후 및 항암 치료에 대한 반응성 예측 방법
CN113834889B (zh) * 2021-09-29 2024-02-13 中国医学科学院北京协和医院 垂体柄阻断综合征生物标志物及其确定方法和应用
US20250304692A1 (en) * 2021-10-29 2025-10-02 La Jolla Institute For Immunology Methods for modulating an immune response to cancer or tumor cells
CN114019163B (zh) * 2021-11-02 2024-07-23 复旦大学附属中山医院 基于活化b细胞表达的结肠癌预后诊断用标记物及其用途
CN113834941B (zh) * 2021-11-02 2024-01-05 复旦大学附属中山医院 基于b细胞表达的结肠癌预后诊断用标记物及其用途
JP7727301B2 (ja) * 2021-11-25 2025-08-21 国立研究開発法人国立がん研究センター がん罹患者の生存期間を予測する方法
US20250035635A1 (en) 2022-03-17 2025-01-30 Institut National De La Sante Et De La Recherche Medicale Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
CN114657252A (zh) * 2022-04-26 2022-06-24 复旦大学 一种用于脑恶性胶质瘤诊断和预后的趋化因子及其应用
EP4604939A1 (de) 2022-10-20 2025-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombinationstherapie zur behandlung von krebs
WO2024192258A2 (en) * 2023-03-14 2024-09-19 Duke University Methods for assessing immune fitness
WO2024215053A1 (ko) * 2023-04-10 2024-10-17 연세대학교 산학협력단 폐암 치료의 반응 및 효능 평가와 예후 예측용 바이오 마커
CN116819066A (zh) * 2023-06-30 2023-09-29 复旦大学附属中山医院 肝癌微环境检测试剂盒
WO2025022162A1 (en) 2023-07-26 2025-01-30 Vilnius University Ex vivo cellular model system comprising heterogenous cells from human lung tumor for the evaluation of drug cytotoxicity in vitro and method thereof
WO2025188566A1 (en) * 2024-03-04 2025-09-12 Ludwig Enterprises, Inc. MRNAs DIFFERENTIALLY EXPRESSED IN CANCER
WO2025219595A1 (en) 2024-04-19 2025-10-23 Biper Therapeutics Method for combination treatments using alkynylbenzenesulphonamides for cancer therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz, Joseph R. Phasenmodulationsenergieübertragungsfluoroimmunassay
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
EP0610774B1 (de) * 1993-02-09 2001-03-28 Becton, Dickinson and Company Automatische Bestimmung der Zellinie schwerer Leukämien durch Flusszytometrie
US5658744A (en) * 1994-07-22 1997-08-19 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying patients having an altered immune status
AU4977896A (en) * 1995-02-17 1996-09-04 Immunotherapy, Inc. Immunotherapy screening, prognosis, and treatment methods and compositions
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0893507A1 (de) * 1997-07-25 1999-01-27 Institut Gustave Roussy Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs
US6892141B1 (en) 2000-03-17 2005-05-10 Hitachi, Ltd. Primer design system
US6656683B1 (en) * 2000-07-05 2003-12-02 Board Of Regents, The University Of Texas System Laser scanning cytology with digital image capture
WO2002068614A2 (en) * 2001-02-26 2002-09-06 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
FR2821605B1 (fr) * 2001-03-01 2003-05-30 Eads Airbus Sa Procede et dispositif pour accelerer la destruction d'au moins deux vortex dans le sillage d'un mobile, en particulier d'un avion
AR036993A1 (es) * 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
EP1399460A4 (de) * 2001-04-27 2005-04-13 Sunnybrook & Women S College H Mit brustkrebs assoziierte gene und deren verwendung
EP1461350A4 (de) 2001-11-30 2006-07-26 Univ Rochester Quantitative multiplex-pcr in echtzeit
WO2003070265A2 (en) * 2002-02-20 2003-08-28 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Hedgehog-related prophylaxis, therapy and diagnosis of gi tract carcinogenesis
ES2350687T3 (es) * 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
PL1651247T3 (pl) 2003-07-18 2009-04-30 Schering Corp Leczeni i diagnozowanie nowotworów przy użyciu limfopoetyny zrębu grasicy
ES2671893T3 (es) * 2004-10-06 2018-06-11 Mayo Foundation For Medical Education And Research B7-H1 y PD-1 en el tratamiento del carcinoma de células renales

Also Published As

Publication number Publication date
EP2420841A3 (de) 2012-09-26
EP2420840A2 (de) 2012-02-22
ES2480690T3 (es) 2014-07-28
EP2241891B1 (de) 2012-10-31
EP3715849B1 (de) 2023-08-09
JP5921602B2 (ja) 2016-05-24
EP2733493B1 (de) 2016-06-22
JP2014158500A (ja) 2014-09-04
DK2733493T3 (en) 2016-09-19
EP2420835A3 (de) 2012-05-30
EP2420837B1 (de) 2014-03-05
EP2420841B1 (de) 2014-12-03
EP2420841A2 (de) 2012-02-22
ES2592169T3 (es) 2016-11-28
ES2785033T3 (es) 2020-10-05
WO2007045996A1 (en) 2007-04-26
EP2420836B1 (de) 2014-03-05
US20220308063A1 (en) 2022-09-29
ES2469102T3 (es) 2014-06-17
EP1777523A1 (de) 2007-04-25
ES2469103T3 (es) 2014-06-17
EP2420835B1 (de) 2014-03-05
US20190178892A1 (en) 2019-06-13
JP2012154944A (ja) 2012-08-16
US20090215053A1 (en) 2009-08-27
JP5256038B2 (ja) 2013-08-07
ES2674560T3 (es) 2018-07-02
EP2420838B1 (de) 2014-04-16
EP2420836A3 (de) 2012-05-30
EP1943520B1 (de) 2011-09-07
EP2420836A2 (de) 2012-02-22
EP2420839A3 (de) 2012-09-19
US11300569B2 (en) 2022-04-12
US20150268245A1 (en) 2015-09-24
JP2009515148A (ja) 2009-04-09
US20140057257A1 (en) 2014-02-27
EP2420838A3 (de) 2012-09-26
EP2420839B1 (de) 2014-04-16
ES2470165T3 (es) 2014-06-23
ES2398907T3 (es) 2013-03-22
EP2420839A2 (de) 2012-02-22
ES2561527T3 (es) 2016-02-26
PL2733493T3 (pl) 2016-12-30
ES2374783T3 (es) 2012-02-22
EP2241891A1 (de) 2010-10-20
US10191059B2 (en) 2019-01-29
EP2420840A3 (de) 2012-08-08
EP2420837A2 (de) 2012-02-22
ES2480691T3 (es) 2014-07-28
EP2420835A2 (de) 2012-02-22
EP3088894B1 (de) 2018-03-28
EP3364191B1 (de) 2020-03-18
EP3715849A1 (de) 2020-09-30
EP1943520A1 (de) 2008-07-16
EP3088894A1 (de) 2016-11-02
EP2420840B1 (de) 2015-11-11
DK2420840T3 (en) 2016-02-08
EP2420838A2 (de) 2012-02-22
JP5789216B2 (ja) 2015-10-07
ES2531659T3 (es) 2015-03-18
US8481271B2 (en) 2013-07-09
EP2420837A3 (de) 2012-05-30
EP2733493A1 (de) 2014-05-21
EP3364191A1 (de) 2018-08-22

Similar Documents

Publication Publication Date Title
ATE523786T1 (de) In-vitro-verfahren zur prognose des fortschreitens einer krebserkrankung und des ausgangs für einen patienten sowie verfahren zur durchführung des verfahrens
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
DE502007006200D1 (de) Verfahren zur verarbeitung von offset-behafteten sensorsignalen sowie für die durchführung des verfahrens ausgebildete sensoranordnung
EP2392678A3 (de) Prognosevorhersage für Kolorektalkrebs
DE602004027600D1 (de) Genexpressionsmarker für die prognose von brustkrebs
WO2007092622A3 (en) Compositions and methods for treating bone
ATE507305T1 (de) Verfahren zur nukleinsäureimmobilisierung
TN2010000140A1 (en) Compositions and methods for use antibodies against sclerostin
MX2012011722A (es) Diseño automatico de tratamientos de fracturamiento hidraulico que utiliza la altura de la fractura y la presion in situ.
NO20075304L (no) Metode for avtagende forkalkning
EP1849757A4 (de) Verfahren zur herstellung einer ungesättigten kohlenwasserstoffverbindung
EP2014783A4 (de) Verfahren zur herstellung von feuerverzinktem stahlblech und feuerverzinktes stahlblech
EP2340258A4 (de) Verfahren zur synthese und anwendungen von inhibitoren von ghrelin-o-acyltransferase als potentielle therapeutische mittel gegen obesitas und diabetes
WO2008103299A8 (en) Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
ATE476100T1 (de) Neues verfahren für die biologische bekämpfung des ausbreitens von legionella pneumophila, und neues desinfektionsmittel, das amöben-protozoen der gattung willaertia enthält
EP1987165A4 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
DE502006006803D1 (de) Verfahren zur herstellung von leder
EP1848834A4 (de) Verfahren zur behandlung von kupferhaltigen materialien
ATE545023T1 (de) Verfahren zur vorhersage der fähigkeit einer zearalenon-analogverbindung für die krebsbehandlung
ATE470453T1 (de) Verfahren zur behandlung von atherosklerose
WO2011015348A3 (en) Responsiveness to angiogenesis inhibitors
WO2009114817A3 (en) Pttg1 as a biomarker for cancer treatment
DE602006016106D1 (de) Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung
ATE463468T1 (de) Verwendung von magnesiumphosphat zur wasserenthärtung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties